Parantaa Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.20 M
- Company Age 4 Year, 5 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.00 M
- Revenue Growth 1096902.39%
- Profit Growth 130488.99%
- Ebitda 89768.42%
- Net Worth 109361.09%
- Total Assets 113273.57%
About Parantaa Drugs
Parantaa Drugs Private Limited (PDPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 February 2021 (Four years 5 days old ). Its registered office is in Kamrup, Assam, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹3.00 M.
Jyotishmoy Bora, Sahadev Dam, Rinji Borah, and One other member serve as directors at the Company.
Company Details
-
Location
Kamrup, Assam, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U85110AS2021PTC020971
-
Company No.
020971
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Feb 2021
-
Date of AGM
26 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Shillong
Industry
Who are the key members and board of directors at Parantaa Drugs?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jyotishmoy Bora
|
Director | 06-Feb-2021 | Current |
|
Sahadev Dam
|
Director | 13-May-2024 | Current |
|
Rinji Borah
|
Additional Director | 28-Jun-2021 | Current |
|
Purnima Bora
|
Additional Director | 28-Jun-2021 | Current |
Financial Performance of Parantaa Drugs.
Parantaa Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1096902.39% increase. The company also saw a substantial improvement in profitability, with a 130488.99% increase in profit. The company's net worth Soared by an impressive increase of 109361.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Parantaa Drugs?
Unlock access to Parantaa Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹3.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Dec 2023 | Others | ₹3.00 M | Open |
How Many Employees Work at Parantaa Drugs?
Parantaa Drugs has a workforce of 7 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Parantaa Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Parantaa Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
